JP2002293747A - Skin preparation for external use - Google Patents
Skin preparation for external useInfo
- Publication number
- JP2002293747A JP2002293747A JP2001096999A JP2001096999A JP2002293747A JP 2002293747 A JP2002293747 A JP 2002293747A JP 2001096999 A JP2001096999 A JP 2001096999A JP 2001096999 A JP2001096999 A JP 2001096999A JP 2002293747 A JP2002293747 A JP 2002293747A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- action
- amino acids
- mucopolysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、皮膚外用剤に関
し、さらに詳しくは、皮膚症状の改善、抗炎症、創傷治
癒、皮膚の老化防止、黒色化した皮膚の美白、肌荒れ改
善等に優れた効果を示し、しかも安定性、安全性や使用
感に優れた皮膚外用剤に関する。TECHNICAL FIELD The present invention relates to an external preparation for skin, and more particularly, to an effect excellent in improvement of skin symptoms, anti-inflammation, wound healing, prevention of skin aging, whitening of blackened skin, improvement of rough skin, etc. And a skin external preparation having excellent stability, safety and usability.
【０００２】[0002]
【従来の技術】近年、皮膚化粧料や皮膚外用剤の分野に
おいて、皮膚機能自体を活性化して、皮膚症状の改善や
抗炎症効果等を有する皮膚外用剤について多くの研究が
なされてきた。皮膚構成細胞の中でも、特に真皮におけ
る線維芽細胞は、膠原線維、弾性線維、基質を産生する
細胞であり、この細胞を賦活、活性化することにより、
皮膚の老化防止、肌荒れ改善等の効果が得られることが
知られている。2. Description of the Related Art In recent years, in the field of skin cosmetics and external preparations for skin, many studies have been made on external preparations for skin which activate skin function itself, improve skin symptoms and have anti-inflammatory effects. Among the skin constituent cells, fibroblasts in the dermis in particular are collagen fibers, elastic fibers, cells that produce a matrix, and by activating and activating these cells,
It is known that effects such as prevention of skin aging and improvement of rough skin can be obtained.
【０００３】従来、このような細胞賦活作用を有する物
質として、アラントイン、動物由来のタンパク質類、ア
スコルビン酸およびその誘導体、ビタミン類、フラボノ
イド類の配糖体を含む植物抽出液といった種々の物質が
使用されてきた。また、可溶性卵殻膜を有効成分として
配合した皮膚外用剤等も提案されている。Conventionally, various substances such as allantoin, animal-derived proteins, ascorbic acid and its derivatives, plant extracts containing glycosides of vitamins and flavonoids have been used as such substances having a cell activating effect. It has been. Also, a skin external preparation and the like containing a soluble eggshell membrane as an active ingredient have been proposed.
【０００４】しかしながら、従来使用されてきた上記の
ような細胞賦活効果を有する成分、あるいは従来提案さ
れている皮膚外用剤等は、作用効果が不十分であった
り、安定性や使用感が悪かったりして、十分満足できる
皮膚外用剤は、未だ開発されていないのが現状である。[0004] However, the conventionally used components having the above-mentioned cell activating effect, or conventionally proposed external preparations for skin, etc., have insufficient action effects, poor stability and feeling of use. At present, a satisfactory skin external preparation has not yet been developed.
【０００５】[0005]
【発明が解決しようとする課題】そこで本発明は、細胞
賦活作用を有する物質の皮膚症状の改善、抗炎症、創傷
治癒、皮膚の老化防止、黒色化した皮膚の美白、肌荒れ
改善等の効果を十分に発揮させ得て、しかも安定性、安
全性や使用感に優れた皮膚外用剤を提供することを目的
とする。Accordingly, the present invention is intended to improve the effects of a substance having a cell activating effect on skin symptoms, anti-inflammation, wound healing, prevention of skin aging, whitening of blackened skin, and improvement of skin roughness. An object of the present invention is to provide an external preparation for skin that can be sufficiently exerted, and that is excellent in stability, safety and usability.
【０００６】[0006]
【課題を解決するための手段】本発明者は、上記目的を
達成するために鋭意研究を重ねた結果、ヒト真皮線維芽
細胞増殖促進作用を有する可溶性卵殻膜と、特定の細胞
賦活作用を有する物質とを併用することにより、相乗効
果的な皮膚症状の改善、抗炎症、創傷治癒、皮膚の老化
防止、黒色化した皮膚の美白、肌荒れ改善等の効果が得
られることを見出し、本発明を完成するに至った。Means for Solving the Problems As a result of intensive studies to achieve the above object, the present inventors have found that a soluble eggshell membrane having a human dermal fibroblast cell growth-promoting action and a specific cell activating action. By using the substance in combination, the present inventors have found that synergistic effects such as improvement of skin symptoms, anti-inflammation, wound healing, prevention of skin aging, whitening of blackened skin, improvement of rough skin, etc. are obtained, and the present invention It was completed.
【０００７】すなわち、本発明は、上記目的を達成する
ために、可溶性卵殻膜、ムコ多糖類、アミノ酸類および
植物由来の生理活性物質を配合したことを特徴とする皮
膚外用剤を提供する。[0007] That is, the present invention provides a skin external preparation characterized by incorporating a soluble eggshell membrane, a mucopolysaccharide, an amino acid and a plant-derived physiologically active substance in order to achieve the above object.
【０００８】[0008]
【発明の実施の形態】本発明に用いられる可溶性卵殻膜
としては、鶏卵、うずら卵等の鳥卵の卵殻の内側に付着
している膜（卵殻膜）を酸剤、アルカリ剤、有機溶剤、
酸化・還元剤等で可溶化処理したものとして一般に知ら
れているもの、例えば、特開昭４８−４０９４３号公
報、特開平１−２７５５１２号公報等に記載の方法によ
って得られるものを挙げることができる。その配合量と
しては、可溶性卵殻膜の細胞に対する作用や製剤の安定
性を考慮し、皮膚外用剤総重量に対して０．０１〜５重
量％であり、特に好ましくは０．１〜３重量％である。
０．０１重量％未満では、得られる皮膚外用剤の上記諸
効果が低下する傾向があり、一方、５重量％を超える
と、得られる皮膚外用剤の安定性の低下等の傾向があ
る。BEST MODE FOR CARRYING OUT THE INVENTION As the soluble eggshell membrane used in the present invention, a membrane (eggs membrane) adhering to the inside of the eggshell of bird eggs such as chicken eggs and quail eggs can be used as an acid agent, an alkali agent, an organic solvent,
Those generally known as those solubilized with an oxidizing / reducing agent, for example, those obtained by the methods described in JP-A-48-40943, JP-A-1-275512, etc. it can. The amount of the compound is 0.01 to 5% by weight, particularly preferably 0.1 to 3% by weight, based on the total weight of the external preparation for skin in consideration of the action of the soluble eggshell membrane on cells and the stability of the preparation. It is.
If the amount is less than 0.01% by weight, the above-mentioned various effects of the obtained external preparation for skin tend to decrease, while if it exceeds 5% by weight, the stability of the obtained external preparation for skin tends to decrease.
【０００９】本発明に用いられるムコ多糖類としては、
ヘキソサミン（多くの場合Ｎ−アセチル化されたグルコ
サミンまたはガラクトサミン）とウロン酸（Ｄ−グルク
ロン酸またはＬ−イズロン酸）よりなる二糖の繰り返し
単位からなる長鎖多糖、あるいはこれらの塩類または誘
導体が用いられ、その具体例としては、特に限定されな
いが、ヒアルロン酸、コンドロイチン硫酸、コンドロイ
チン、デルマタン硫酸、ヘパラン硫酸、ヘパリン、ケラ
タン硫酸等が挙げられる。これらのムコ多糖類は、必要
に応じて１種用いることも、２種以上を用いることもで
きる。また、その配合量としては、ムコ多糖類の皮膚に
対する作用や製剤の安定性を考慮し、皮膚外用剤総重量
に対して０．００１〜１０重量％が好ましく、特に好ま
しくは０．０１〜５重量％である。０．００１重量％未
満では、得られる皮膚外用剤の上記諸効果が低下する傾
向があり、一方、１０重量％を超えると、得られる皮膚
外用剤の安定性の低下等の傾向がある。The mucopolysaccharide used in the present invention includes:
A long-chain polysaccharide composed of a repeating unit of a disaccharide composed of hexosamine (often N-acetylated glucosamine or galactosamine) and uronic acid (D-glucuronic acid or L-iduronic acid), or a salt or derivative thereof is used. Specific examples thereof include, but are not particularly limited to, hyaluronic acid, chondroitin sulfate, chondroitin, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, and the like. One of these mucopolysaccharides may be used alone, or two or more of them may be used as necessary. The amount of the compound is preferably 0.001 to 10% by weight, particularly preferably 0.01 to 5%, based on the total weight of the external preparation for skin in consideration of the action of mucopolysaccharide on the skin and the stability of the preparation. % By weight. When the amount is less than 0.001% by weight, the above-mentioned various effects of the obtained external preparation for skin tend to decrease. On the other hand, when the amount exceeds 10% by weight, the stability of the external preparation for skin tends to decrease.
【００１０】本発明に用いられるアミノ酸類としては、
コラーゲンおよびエラスチン産生促進作用かあるいは、
エラスターゼ活性阻害作用を有するもので、特に限定さ
れないが、グリシン（Glycine）、プロリン（Prolin
e）、アラニン（Alanine）、ヒドロキシプロリン（Hydr
oxyproline）、グルタミン酸（Glutamic acid）、アル
ギニン（Arginine）、アスパラギン酸（Aspartic aci
d）、セリン（Serine）、リジン（Lysine）、バリン（V
aline）、ロイシン（Leucine）、トレオニン（Threonin
e）、フェニルアラニン（Phenylalanine）、ヒスチジン
（Histidine）、シスチン（Cystine）、システイン酸
（Cysteic acid）、メチオニン（Methionine）、イソロ
イシン（Isoleucine）、チロシン（Tyrosine）、ヒドロ
キシリジン（Hydroxylysine）、デスモシン（Desmosin
e）、リシノノルロイシン（Lysinonorleucine）、等の
アミノ酸が挙げられ、さらに、オリゴペプチド類、ポリ
ペプチド類、タンパク質類としては、特に限定されない
が、ダイズ抽出液、シルク抽出液、加水分解シルク液等
が挙げられ、なおさらに、それらの誘導体等が挙げられ
る。これらのアミノ酸類は、必要に応じて１種用いるこ
とも、２種以上を用いることもできる。また、その配合
量としては、アミノ酸類の細胞に対する作用や製剤の安
定性を考慮し、皮膚外用剤総重量に対して、０．０００
００１〜１０重量％が好ましく、特に好ましくは０．０
００１〜５重量％である。０．０００００１重量％未満
では、得られる皮膚外用剤の上記諸効果が低下する傾向
があり、一方、１０重量％を超えると、得られる皮膚外
用剤の安定性の低下等の傾向がある。The amino acids used in the present invention include:
Promotes collagen and elastin production, or
It has an elastase activity inhibitory effect, and is not particularly limited, but includes glycine (Glycine), proline (Prolin)
e), Alanine, hydroxyproline (Hydr)
oxyproline), glutamic acid (Glutamic acid), arginine (Arginine), aspartic acid (Aspartic aci)
d), Serine, Lysine, Valine (V
aline), leucine (Leucine), threonine (Threonin)
e), Phenylalanine, Histidine, Cystine, Cysteic acid, Methionine, Isoleucine, Tyrosine, Hydroxylysine, Desmosin
e), amino acids such as lysinonorleucine, and the like. Oligopeptides, polypeptides, and proteins are not particularly limited, and soybean extract, silk extract, hydrolyzed silk solution, and the like. And furthermore, their derivatives and the like. One of these amino acids may be used alone, or two or more thereof may be used as necessary. In addition, considering the action of amino acids on cells and the stability of the preparation, the amount thereof is 0.000 to the total weight of the external preparation for skin.
001 to 10% by weight is preferable, and particularly preferably 0.0 to 10% by weight.
001 to 5% by weight. If the amount is less than 0.000001% by weight, the above-mentioned various effects of the obtained external preparation for skin tend to decrease, while if it exceeds 10% by weight, the stability of the obtained external preparation for skin tends to decrease.
【００１１】本発明に用いられる植物由来の生理活性物
質としては、美白作用（メラニン産生抑制作用）、抗炎
症作用、抗アレルギー作用、抗酸化作用等の生理活性を
示すものが用いられ、その具体例としては、特に限定さ
れないが、エンメイソウ抽出物、カミツレ抽出物、リン
ドウ抽出物、カンゾウ抽出物、ボタン抽出物、センブリ
抽出物、チンピ抽出物、アーモンド抽出物、ニンジン抽
出物、エンドウ抽出物、ユキノシタ抽出物、クワ抽出物
等が挙げられる。これらの植物由来の生理活性物質は、
必要に応じて１種用いることも、２種以上を用いること
もできる。また、その配合量としては、植物由来の生理
活性物質の皮膚に対する作用や製剤の安定性を考慮し、
皮膚外用剤総重量に対して、０．０１〜１０重量％が好
ましく、特に好ましくは０．１〜５重量％である。０．
０１重量％未満では、得られる皮膚外用剤の上記諸効果
が低下する傾向があり、一方、１０重量％を超えると、
得られる皮膚外用剤の安定性の低下等の傾向がある。As the plant-derived physiologically active substance used in the present invention, those exhibiting physiological activities such as whitening action (melanin production inhibitory action), anti-inflammatory action, anti-allergic action and antioxidant action are used. Examples include, but are not particularly limited to, lime extract, chamomile extract, gentian extract, licorice extract, button extract, assembly extract, chimpanzee extract, almond extract, carrot extract, pea extract, saxifrage Extract, mulberry extract and the like. These plant-derived physiologically active substances are
One type may be used as needed, or two or more types may be used. In addition, considering the action of the plant-derived physiologically active substance on the skin and the stability of the formulation,
It is preferably 0.01 to 10% by weight, particularly preferably 0.1 to 5% by weight, based on the total weight of the external preparation for skin. 0.
When the amount is less than 01% by weight, the above-mentioned various effects of the obtained external preparation for skin tend to decrease.
There is a tendency for the stability of the obtained external preparation for skin to decrease.
【００１２】本発明の皮膚外用剤には、上記した各成分
のほかに、通常皮膚外用剤に配合される保湿剤、紫外線
防御剤、薬効剤等を配合することができる。保湿剤とし
ては、ポリエチレングリコール、プロピレングリコー
ル、グリセリン、キトサン誘導体、糖類、水溶性ポリマ
ー等を挙げることができる。紫外線防御剤としては、パ
ラアミノ安息香酸誘導体、サリチル酸誘導体、ケイ皮酸
誘導体、ウロカニン酸誘導体等の紫外線吸収剤、酸化チ
タン、酸化亜鉛、タルク等の紫外線散乱剤等を挙げるこ
とができる。薬効剤としては、外来菌の異常増殖による
感染症を防止するためのトリクロサン、ビオゾール、塩
化ベンザルコニウム、塩化ベンゼトニウム、フェノキシ
エタノール、パラベン類等の抗菌剤、栄養補給、血行促
進、５α−リダクターゼの制御を目的とした養毛剤成分
等を挙げることができる。The external preparation for skin of the present invention may contain, in addition to the above-mentioned components, a humectant, an ultraviolet ray protective agent, a medicinal agent and the like which are usually added to the external preparation for skin. Examples of the humectant include polyethylene glycol, propylene glycol, glycerin, chitosan derivatives, saccharides, and water-soluble polymers. Examples of the ultraviolet ray protective agent include an ultraviolet ray absorbent such as a paraaminobenzoic acid derivative, a salicylic acid derivative, a cinnamic acid derivative and an urocanic acid derivative, and an ultraviolet ray scattering agent such as titanium oxide, zinc oxide and talc. Pharmaceutical agents include antimicrobial agents such as triclosan, biosol, benzalkonium chloride, benzethonium chloride, phenoxyethanol, and parabens for preventing infectious diseases caused by abnormal growth of foreign bacteria, nutritional supplementation, blood circulation promotion, and control of 5α-reductase. And a hair restorer component for the purpose.
【００１３】本発明の皮膚外用剤には、さらに、本発明
の目的を損なわない範囲で、油脂類、ロウ類、炭化水素
類、脂肪酸類、エステル類、界面活性剤、高分子化合
物、酸化防止剤、金属イオン封鎖剤、色素、香料、ｐＨ
調整剤、保存剤等を適宜配合することができる。The external preparation for skin of the present invention further comprises fats and oils, waxes, hydrocarbons, fatty acids, esters, surfactants, high molecular compounds, antioxidants, as long as the object of the present invention is not impaired. Agent, sequestering agent, dye, fragrance, pH
A regulator, a preservative, and the like can be appropriately blended.
【００１４】本発明の皮膚外用剤は、化粧品、医薬部外
品または医薬品として広く使用することができ、その剤
型も、化粧水、美容液、水性ジェル等のローション類か
ら、乳液類、クリーム類、軟膏、油剤等の各種の通常使
用される外用剤としての剤型にすることができる。The external preparation for skin of the present invention can be widely used as cosmetics, quasi-drugs or pharmaceuticals, and can be used in lotions such as lotions, serums, aqueous gels, emulsions, creams, etc. , Ointments, oils, and various other commonly used external preparations.
【００１５】[0015]
【実施例】以下、実施例および比較例により本発明をさ
らに具体的に説明するが、本発明は以下の実施例に限定
されるものではない。The present invention will be described more specifically with reference to the following examples and comparative examples, but the present invention is not limited to the following examples.
【００１６】実施例１、比較例１〜８ 化粧水を表１に示す処方にて常法により製造した。Example 1, Comparative Examples 1 to 8 Lotions were prepared according to the formulation shown in Table 1 by a conventional method.
【００１７】[0017]
【表１】 [Table 1]
【００１８】この実施例１と比較例１〜８の各化粧水
を、しみ、小皺、乾燥肌等を訴える女性被験者（２５〜
５５才）３０人を対象に、１日２回（朝・夕）適量を顔
面へ連続１ヶ月間使用させ、使用前後の皮膚状態を評価
した。評価は、実施例１および比較例１〜８の各化粧水
それぞれをブラインドにて使用させ、使用試験開始前と
使用試験終了後の皮膚の状態を観察して評価した。評価
は「I：改善」「II：やや改善」「III：変化なし」の三
段階で行い、その結果を表２に示した。Each of the lotions of Example 1 and Comparative Examples 1 to 8 was applied to a female subject (25 to 25) complaining of spots, fine wrinkles, dry skin, etc.
For 30 subjects (55 years old), an appropriate amount was applied to the face twice a day (morning and evening) for one continuous month, and the skin condition before and after use was evaluated. The evaluation was performed by using each of the lotions of Example 1 and Comparative Examples 1 to 8 with a blind, and observing and evaluating the state of the skin before the start of the use test and after the end of the use test. The evaluation was performed in three stages of “I: improvement”, “II: slight improvement”, and “III: no change”, and the results are shown in Table 2.
【００１９】[0019]
【表２】 [Table 2]
【００２０】実施例２、比較例９〜１６ 乳液を表３に示す処方にて常法により製造した。Example 2, Comparative Examples 9-16 Emulsions were prepared according to the formulation shown in Table 3 by a conventional method.
【００２１】[0021]
【表３】 [Table 3]
【００２２】この実施例２と比較例９〜１６の各乳液
を、しみ、小皺、乾燥肌等を訴える女性被験者（２５〜
５５才）３０人を対象に、１日２回（朝・夕）適量を顔
面へ連続１ヶ月間使用させ、使用前後の皮膚状態を評価
した。評価は、実施例２および比較例９〜１６の各乳液
それぞれをブラインドにて使用させ、使用試験開始前と
使用試験終了後の皮膚の状態を観察して評価した。評価
は「I：改善」「II：やや改善」「III：変化なし」の三
段階で行い、その結果を表４に示した。Each of the emulsions of Example 2 and Comparative Examples 9 to 16 was applied to female subjects (25 to 25) who complained of spots, fine wrinkles, dry skin, etc.
For 30 subjects (55 years old), an appropriate amount was applied to the face twice a day (morning and evening) for one continuous month, and the skin condition before and after use was evaluated. The evaluation was carried out by blindly using each of the emulsions of Example 2 and Comparative Examples 9 to 16, and evaluated by observing the state of the skin before the start of the use test and after the end of the use test. The evaluation was performed in three stages: "I: improved", "II: slightly improved", and "III: no change". The results are shown in Table 4.
【００２３】[0023]
【表４】 [Table 4]
【００２４】実施例３、比較例１７〜２４ クリームを表５に示す処方にて常法により製造した。Example 3, Comparative Examples 17 to 24 Creams were prepared according to the formulation shown in Table 5 by a conventional method.
【００２５】[0025]
【表５】 [Table 5]
【００２６】この実施例３と比較例１７〜２４の各クリ
ームを、しみ、小皺、乾燥肌等を訴える女性被験者（２
５〜５５才）３０人を対象に、１日２回（朝・夕）適量
を顔面へ連続１ヶ月間使用させ、使用前後の皮膚状態を
評価した。評価は、実施例３および比較例１７〜２４の
各クリームそれぞれをブラインドにて使用させ、使用試
験開始前と使用試験終了後の皮膚の状態を観察して評価
した。評価は「I：改善」「II：やや改善」「III：変化
なし」の三段階で行い、その結果を表６に示した。Each of the creams of Example 3 and Comparative Examples 17 to 24 was applied to a female subject (2) complaining of spots, wrinkles, dry skin, etc.
For 30 subjects (5 to 55 years old), an appropriate amount was applied to the face twice a day (morning and evening) for one continuous month, and the skin condition before and after use was evaluated. The evaluation was performed by using each of the creams of Example 3 and Comparative Examples 17 to 24 in a blind, and observing and evaluating the skin condition before the start of the use test and after the end of the use test. The evaluation was performed in three stages: "I: improved", "II: slightly improved", and "III: no change". The results are shown in Table 6.
【００２７】[0027]
【表６】 [Table 6]
【００２８】表２に示されるように、可溶性卵殻膜、ム
コ多糖類、アミノ酸類および植物由来の生理活性物質の
各種成分を単独で配合した比較例２〜５、可溶性卵殻膜
とムコ多糖類を配合した比較例６、可溶性卵殻膜と植物
由来の生理活性物質を配合した比較例７、可溶性卵殻膜
とアミノ酸類を配合した比較例８、もしくは配合してい
ない比較例１と比較して、各種成分を合わせ配合した本
発明の実施例１では、各種成分を合わせ配合した相乗効
果により、被験者の７７〜８７％が皮膚の状態に改善が
あったと認めた。As shown in Table 2, the soluble eggshell membranes, mucopolysaccharides, amino acids and various components of physiologically active substances derived from plants were independently blended. In comparison with Comparative Example 6 in which the compound was mixed, Comparative Example 7 in which a soluble eggshell membrane was mixed with a physiologically active substance derived from plants, Comparative Example 8 in which a soluble eggshell membrane was mixed with amino acids, or Comparative Example 1 in which no compound was mixed, In Example 1 of the present invention in which the components were combined and mixed, 77-87% of the subjects recognized that the skin condition was improved due to the synergistic effect of combining and mixing the various components.
【００２９】表４に示されるように、各種成分を単独で
配合した比較例１０〜１３、可溶性卵殻膜とムコ多糖類
を配合した比較例１４、可溶性卵殻膜と植物由来の生理
活性物質を配合した比較例１５、可溶性卵殻膜とアミノ
酸類を配合した比較例１６、もしくは配合していない比
較例９と比較して、各種成分を合わせ配合した本発明の
実施例２では、各種成分を合わせ配合した相乗効果によ
り、被験者の７３〜８７％が皮膚の状態に改善があった
と認めた。As shown in Table 4, Comparative Examples 10 to 13 in which various components were blended alone, Comparative Example 14 in which a soluble eggshell membrane and mucopolysaccharide were blended, and a soluble eggshell membrane and a plant-derived physiologically active substance were blended Comparative Example 15, Comparative Example 16 in which a soluble eggshell membrane and an amino acid were blended, or Comparative Example 9 in which no amino acid was blended. In Example 2 of the present invention in which various components were combined and blended, various components were combined and blended. Due to the synergistic effect, 73-87% of the subjects recognized that their skin condition was improved.
【００３０】表６に示されるように、各種成分を単独で
配合した比較例１８〜２１、可溶性卵殻膜とムコ多糖類
を配合した比較例２２、可溶性卵殻膜と植物由来の生理
活性物質を配合した比較例２３、可溶性卵殻膜とアミノ
酸類を配合した比較例２４、もしくは配合していない比
較例１７と比較して、各種成分を合わせ配合した本発明
の実施例３では、各種成分を合わせ配合した相乗効果に
より、被験者の８０〜８７％が皮膚の状態に改善があっ
たと認めた。As shown in Table 6, Comparative Examples 18 to 21 in which various components were blended alone, Comparative Example 22 in which soluble shell membrane and mucopolysaccharide were blended, and soluble shell membrane and plant-derived physiologically active substance were blended In Comparative Example 23, Comparative Example 24 in which a soluble eggshell membrane and an amino acid were blended, or Comparative Example 17 in which no amino acid was blended, in Example 3 of the present invention in which various components were combined and blended, various components were combined and blended. Due to the synergistic effect, 80-87% of the subjects recognized that their skin condition was improved.
【００３１】なお、上記評価試験における使用期間にお
いて、いずれの実施例の製品を使用した群においても、
痒みまたは紅斑を伴う痛み等の皮膚刺激やアレルギー反
応等の皮膚症状を訴えた被験者はいなかった。また、配
合成分の沈降、変質、乳化状態の悪化等も認められなか
った。During the period of use in the above evaluation test, in the group using the product of any of the examples,
None of the subjects complained of skin irritation such as pain with itching or erythema or skin symptoms such as allergic reaction. In addition, sedimentation, alteration, deterioration of the emulsified state, and the like of the components were not observed.
【００３２】[0032]
【本発明の効果】本発明の皮膚外用剤は、可溶性卵殻膜
を始めとする一定の各種成分を合わせ配合した相乗効果
により、優れたヒト真皮線維芽細胞増殖促進作用を有
し、優れた皮膚症状の改善、抗炎症、創傷治癒、皮膚の
老化防止、黒色化した皮膚の美白、肌荒れ改善等の効果
を有し、かつ安定性、安全性や使用感にも優れている。EFFECT OF THE INVENTION The external preparation for skin of the present invention has an excellent human dermal fibroblast proliferation-promoting action due to a synergistic effect obtained by combining and mixing certain components such as a soluble eggshell membrane, and an excellent skin. It has the effects of improving symptoms, anti-inflammation, wound healing, preventing skin aging, whitening blackened skin, improving rough skin, etc., and is also excellent in stability, safety and usability.
フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｋ 31/198 Ａ６１Ｋ 31/198 ４Ｃ２０６ 31/726 31/726 35/54 35/54 38/00 Ａ６１Ｐ 17/16 Ａ６１Ｐ 17/16 Ａ６１Ｋ 37/02 Ｆターム(参考） 4C083 AA071 AA072 AA082 AA111 AA112 AC022 AC122 AC352 AC422 AC432 AC442 AC581 AC582 AD152 AD282 AD311 AD312 AD411 AD412 AD452 CC04 CC05 DD23 DD27 DD31 EE12 EE16 4C084 AA02 AA03 BA44 MA16 MA22 MA28 MA63 NA03 NA05 ZA891 ZA892 ZB111 ZB112 ZB131 ZB132 ZB211 ZB212 ZC201 ZC202 ZC211 ZC212 4C086 AA01 AA02 EA25 GA02 MA16 MA22 MA28 MA63 NA03 NA05 ZA89 ZB11 ZB13 ZB21 ZC21 4C087 AA01 AA02 BB61 CA03 CA47 MA17 MA22 MA28 MA63 NA03 NA05 ZA89 ZB11 ZB13 ZB21 ZC21 4C088 AB26 AB58 AB61 AB66 AC01 BA08 BA37 CA03 MA02 MA08 MA63 NA03 NA05 ZA89 ZB11 ZB13 ZB21 ZC21 4C206 AA01 AA02 FA53 MA36 MA42 MA48 MA83 NA03 NA05 ZA89 ZB11 ZB13 ZB21 ZC20 ZC21Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat II (reference) A61K 31/198 A61K 31/198 4C206 31/726 31/726 35/54 35/54 38/00 A61P 17/16 A61P 17 / 16 A61K 37/02 F term (reference) 4C083 AA071 AA072 AA082 AA111 AA112 AC022 AC122 AC352 AC422 AC432 AC442 AC581 AC582 AD152 AD282 AD311 AD312 AD411 AD412 AD452 CC04 CC05 DD23 DD27 DD31 EE12 EE16 4C084 AA02MA03 MA03MA03 MA03 MA03MA03 ZA892 ZB111 ZB112 ZB131 ZB132 ZB211 ZB212 ZC201 ZC202 ZC211 ZC212 4C086 AA01 AA02 EA25 GA02 MA16 MA22 MA28 MA63 NA03 NA05 ZA89 ZB11 ZB13 ZB21 ZC21 4C087 AA01 AA02 BB61 CA03 MA47 MA17 MA03 Z0321 BA08 BA37 CA03 MA02 MA08 MA63 NA03 NA05 ZA89 ZB11 ZB13 ZB21 ZC21 4C206 AA01 AA02 FA53 MA36 MA42 MA48 MA83 NA03 NA05 ZA89 ZB11 ZB13 ZB21 ZC20 ZC21
Claims (5)
および植物由来の生理活性物質を配合したことを特徴と
する皮膚外用剤。1. An external preparation for skin, comprising a soluble eggshell membrane, mucopolysaccharides, amino acids and a physiologically active substance derived from plants.
からなる多糖（グリコサミノグリカン）、およびこれら
の塩類または誘導体よりなる群より選ばれた１種または
２種以上である請求項１に記載の皮膚外用剤。2. The mucopolysaccharide according to claim 1, wherein the mucopolysaccharide is one or more selected from the group consisting of a polysaccharide (glycosaminoglycan) comprising hexosamine and uronic acid, and salts or derivatives thereof. External preparation for skin.
チン産生促進作用かあるいは、エラスターゼ活性阻害作
用を有する、アミノ酸、オリゴペプチド類、ポリペプチ
ド類、タンパク質類、ならびにそれら誘導体よりなる群
より選ばれた１種または２種以上である請求項１または
２に記載の皮膚外用剤。3. An amino acid selected from the group consisting of amino acids, oligopeptides, polypeptides, proteins, and derivatives thereof, wherein the amino acids have a collagen or elastin production promoting action or an elastase activity inhibiting action. Or the external preparation for skin according to claim 1 or 2 which is two or more kinds.
（メラニン産生抑制作用）、抗炎症作用、抗アレルギー
作用、抗酸化作用等の生理活性を示すものから選ばれた
１種または２種以上である請求項１〜３のいずれかに記
載の皮膚外用剤。4. A plant-derived physiologically active substance is selected from those exhibiting physiological activities such as whitening action (melanin production inhibitory action), anti-inflammatory action, anti-allergic action, antioxidant action and the like. The external preparation for skin according to any one of claims 1 to 3, which is:
〜４のいずれかに記載の皮膚外用剤。5. The skin external preparation is a skin cosmetic.
5. The external preparation for skin according to any one of items 1 to 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001096999A JP2002293747A (en) | 2001-03-29 | 2001-03-29 | Skin preparation for external use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001096999A JP2002293747A (en) | 2001-03-29 | 2001-03-29 | Skin preparation for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002293747A true JP2002293747A (en) | 2002-10-09 |
Family
ID=18950844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001096999A Pending JP2002293747A (en) | 2001-03-29 | 2001-03-29 | Skin preparation for external use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002293747A (en) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004203812A (en) * | 2002-12-26 | 2004-07-22 | Kanebo Ltd | Oral composition and bleaching agent containing the same as essential component |
| JP2004217584A (en) * | 2003-01-16 | 2004-08-05 | Naris Cosmetics Co Ltd | Skin care preparation for external use |
| JP2005145889A (en) * | 2003-11-14 | 2005-06-09 | Lion Corp | Medicinal composition, germicidal agent and oral composition, each containing egg shell membrane and amino compound |
| JP2005343887A (en) * | 2004-05-28 | 2005-12-15 | Kao Corp | Elastase inhibitor |
| JP2005350435A (en) * | 2004-06-14 | 2005-12-22 | Coletica | Synthesis of loxl (lysyl oxidase-like) isoform for stimulating formation of elastic fiber and stimulation of activity |
| JP2007051087A (en) * | 2005-08-17 | 2007-03-01 | Noevir Co Ltd | Collagen production promoter, skin care external preparation and oral medicine using the same |
| JP2008056569A (en) * | 2006-08-29 | 2008-03-13 | Fujifilm Corp | External preparation for skin |
| JP2008056570A (en) * | 2006-08-29 | 2008-03-13 | Fujifilm Corp | External preparation for skin |
| JP2010059196A (en) * | 2009-11-16 | 2010-03-18 | Basf Beauty Care Solutions France Sas | Synthesis of loxl (lysyl oxidase-like) isoform for stimulating formation of elastic fiber, and stimulation of activity |
| KR20110094017A (en) * | 2008-11-07 | 2011-08-19 | 클록스 테크놀로지스 인크. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| JP2012232976A (en) * | 2011-04-18 | 2012-11-29 | Toyo Shinyaku Co Ltd | Whitening composition, skin-care preparation for external use and food and drink which each contain the same, and method for producing the whitening composition |
| US8685466B2 (en) | 2009-07-17 | 2014-04-01 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US8986719B2 (en) | 2005-11-09 | 2015-03-24 | Klox Technologies Inc. | Teeth whitening compositions and methods |
| US9345648B2 (en) | 2006-11-09 | 2016-05-24 | Klox Technologies Inc. | Photoactivatable oxygen-evolving compositions and methods for teeth whitening |
| US9655829B2 (en) | 2012-09-14 | 2017-05-23 | Valeant Pharmaceuticals International, Inc. | Compositions and methods for teeth whitening |
| CN107320357A (en) * | 2017-08-08 | 2017-11-07 | 深圳丝爱肌化妆品有限公司 | A kind of cosmetics containing polysaccharide |
| US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| US10213373B2 (en) | 2012-04-20 | 2019-02-26 | Klox Technologies, Inc. | Chromophore combinations for biophotonic uses |
| US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
| US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
| WO2022080287A1 (en) * | 2020-10-14 | 2022-04-21 | 株式会社成和化成 | Collagen production promoter, and skin cosmetic containing said collagen production promoter |
| US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
| CN116251231A (en) * | 2022-06-20 | 2023-06-13 | 江苏东方妍美生物技术发展有限公司 | Cosmetic filling material for injection and preparation method thereof |
-
2001
- 2001-03-29 JP JP2001096999A patent/JP2002293747A/en active Pending
Cited By (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004203812A (en) * | 2002-12-26 | 2004-07-22 | Kanebo Ltd | Oral composition and bleaching agent containing the same as essential component |
| JP2004217584A (en) * | 2003-01-16 | 2004-08-05 | Naris Cosmetics Co Ltd | Skin care preparation for external use |
| JP2005145889A (en) * | 2003-11-14 | 2005-06-09 | Lion Corp | Medicinal composition, germicidal agent and oral composition, each containing egg shell membrane and amino compound |
| JP4625625B2 (en) * | 2003-11-14 | 2011-02-02 | ライオン株式会社 | Disinfectant and composition for oral cavity containing the disinfectant |
| JP2005343887A (en) * | 2004-05-28 | 2005-12-15 | Kao Corp | Elastase inhibitor |
| JP2005350435A (en) * | 2004-06-14 | 2005-12-22 | Coletica | Synthesis of loxl (lysyl oxidase-like) isoform for stimulating formation of elastic fiber and stimulation of activity |
| JP4527451B2 (en) * | 2004-06-14 | 2010-08-18 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス | Stimulation of synthesis and activity of LOXL (lysyl oxidase-like) isoforms to stimulate the formation of elastic fibers |
| JP2007051087A (en) * | 2005-08-17 | 2007-03-01 | Noevir Co Ltd | Collagen production promoter, skin care external preparation and oral medicine using the same |
| US8986719B2 (en) | 2005-11-09 | 2015-03-24 | Klox Technologies Inc. | Teeth whitening compositions and methods |
| JP2008056569A (en) * | 2006-08-29 | 2008-03-13 | Fujifilm Corp | External preparation for skin |
| JP2008056570A (en) * | 2006-08-29 | 2008-03-13 | Fujifilm Corp | External preparation for skin |
| US9345648B2 (en) | 2006-11-09 | 2016-05-24 | Klox Technologies Inc. | Photoactivatable oxygen-evolving compositions and methods for teeth whitening |
| KR101717792B1 (en) | 2008-11-07 | 2017-03-17 | 클록스 테크놀로지스 인크. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| KR101835047B1 (en) | 2008-11-07 | 2018-03-08 | 클록스 테크놀로지스 인크. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| US11691025B2 (en) | 2008-11-07 | 2023-07-04 | Klox Technologies Inc. | Methods and compositions for reversing or mitigating skin aging |
| JP2013253109A (en) * | 2008-11-07 | 2013-12-19 | Klox Technologies Inc | Combination of oxidant and photoactivator for healing wound |
| JP2013253110A (en) * | 2008-11-07 | 2013-12-19 | Klox Technologies Inc | Oxidative photoactivated skin rejuvenation composition including hyaluronic acid, glucosamine and allantoin |
| US8632822B2 (en) | 2008-11-07 | 2014-01-21 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
| US8637086B2 (en) | 2008-11-07 | 2014-01-28 | Klox Technologies Inc. | Method for acne treatment using an oxidative-photoactivated composition |
| US8658219B2 (en) | 2008-11-07 | 2014-02-25 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| US11020609B2 (en) | 2008-11-07 | 2021-06-01 | Klox Technologies Inc. | Methods and compositions for treatment of pigmented lesions |
| US8911791B2 (en) | 2008-11-07 | 2014-12-16 | Klox Technologies Inc. | Method for acne treatment using an oxidative-photoactivated composition |
| US8974833B2 (en) | 2008-11-07 | 2015-03-10 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
| JP2012508190A (en) * | 2008-11-07 | 2012-04-05 | クロクス テクノロジーズ インコーポレイテッド | Oxidative photo-activated skin regenerating composition comprising hyaluronic acid, glucosamine, and allantoin |
| US8986745B2 (en) | 2008-11-07 | 2015-03-24 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| JP2012508189A (en) * | 2008-11-07 | 2012-04-05 | クロクス テクノロジーズ インコーポレイテッド | Combination of oxidant and photoactivator for wound healing |
| JP2016020386A (en) * | 2008-11-07 | 2016-02-04 | クロクス テクノロジーズ インコーポレイテッド | Oxidative photoactivated skin rejuvenation composition including hyaluronic acid, glucosamine, and allantoin |
| KR20110094017A (en) * | 2008-11-07 | 2011-08-19 | 클록스 테크놀로지스 인크. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| US9375446B2 (en) | 2008-11-07 | 2016-06-28 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| JP2016193950A (en) * | 2008-11-07 | 2016-11-17 | クロクス テクノロジーズ インコーポレイテッド | Oxidative photoactivated skin rejuvenation composition including hyaluronic acid, glucosamine, and allantoin |
| US10758744B2 (en) | 2008-11-07 | 2020-09-01 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the wounds |
| US9597349B2 (en) | 2008-11-07 | 2017-03-21 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
| US10485986B2 (en) | 2008-11-07 | 2019-11-26 | Klox Technologies Inc. | Methods and compositions for treatment of pigmented lesions |
| US10384072B2 (en) | 2008-11-07 | 2019-08-20 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
| JP2017160271A (en) * | 2008-11-07 | 2017-09-14 | クロクス テクノロジーズ インコーポレイテッド | Oxidative photoactivated skin rejuvenation composition including hyaluronic acid, glucosamine, and allantoin |
| US10149985B2 (en) | 2008-11-07 | 2018-12-11 | Klox Technologies Inc. | Methods and compositions for treating rosacea |
| KR101810148B1 (en) * | 2008-11-07 | 2017-12-19 | 클록스 테크놀로지스 인크. | Combination of an oxidant and a photoactivator for the healing of wounds |
| US8986746B2 (en) | 2009-07-17 | 2015-03-24 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US8685466B2 (en) | 2009-07-17 | 2014-04-01 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US10322179B2 (en) | 2009-07-17 | 2019-06-18 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US10471147B2 (en) | 2009-07-17 | 2019-11-12 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US9603929B2 (en) | 2009-07-17 | 2017-03-28 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfecton and treatment of oral disease |
| US11141482B2 (en) | 2009-07-17 | 2021-10-12 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| JP2010059196A (en) * | 2009-11-16 | 2010-03-18 | Basf Beauty Care Solutions France Sas | Synthesis of loxl (lysyl oxidase-like) isoform for stimulating formation of elastic fiber, and stimulation of activity |
| JP2012232976A (en) * | 2011-04-18 | 2012-11-29 | Toyo Shinyaku Co Ltd | Whitening composition, skin-care preparation for external use and food and drink which each contain the same, and method for producing the whitening composition |
| US11723854B2 (en) | 2012-04-20 | 2023-08-15 | Fle International S.R.L. | Biophotonic compositions and methods for providing biophotonic treatment |
| US10213373B2 (en) | 2012-04-20 | 2019-02-26 | Klox Technologies, Inc. | Chromophore combinations for biophotonic uses |
| US10376455B2 (en) | 2012-04-20 | 2019-08-13 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
| US11331257B2 (en) | 2012-04-20 | 2022-05-17 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
| US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
| US9655829B2 (en) | 2012-09-14 | 2017-05-23 | Valeant Pharmaceuticals International, Inc. | Compositions and methods for teeth whitening |
| US11324823B2 (en) | 2013-03-14 | 2022-05-10 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
| US10772990B2 (en) | 2014-04-01 | 2020-09-15 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
| CN107320357B (en) * | 2017-08-08 | 2020-09-01 | 深圳丝爱肌化妆品有限公司 | Cosmetic containing polysaccharide |
| CN107320357A (en) * | 2017-08-08 | 2017-11-07 | 深圳丝爱肌化妆品有限公司 | A kind of cosmetics containing polysaccharide |
| WO2022080287A1 (en) * | 2020-10-14 | 2022-04-21 | 株式会社成和化成 | Collagen production promoter, and skin cosmetic containing said collagen production promoter |
| CN116251231A (en) * | 2022-06-20 | 2023-06-13 | 江苏东方妍美生物技术发展有限公司 | Cosmetic filling material for injection and preparation method thereof |
| CN116251231B (en) * | 2022-06-20 | 2024-03-29 | 成都西宏妍美生物技术有限公司 | Cosmetic filling material for injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002293747A (en) | Skin preparation for external use | |
| US4707354A (en) | Mature skin treatment and protectant compositions and methods of using same | |
| US20080108681A1 (en) | Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions | |
| CA2701378C (en) | Seaweed-derived cosmetic compositions | |
| KR20040006007A (en) | Acidic composition for external use and agent for accelerating infiltration of cosmetic preparation, hair-growing agent, and preparation for external use each containing the composition into skin or the like | |
| CN108135972B (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
| CN106691923B (en) | Composition and preparation for cosmetic repair, and preparation method and application thereof | |
| JP2002053428A (en) | Skin care preparation | |
| JPH06279227A (en) | Dermatic external preparation and cosmetic | |
| ES2932550T3 (en) | Stem cell stimulating compositions and methods for treating melasma | |
| US6589540B1 (en) | Cosmetic composition for skin care containing retinol and epidermal growth factor | |
| JP2015533190A (en) | Modified hyaluronic acid derivatives and uses thereof | |
| JP2002173449A (en) | Hair-growing agent | |
| JPH09183718A (en) | Composition suitable for external application | |
| JP2019523300A (en) | Skin care products and their use | |
| JP3172753B2 (en) | Biological hyaluronic acid synthesis promoter | |
| JP2001131049A (en) | Skin preparation for external use | |
| JP2001172167A (en) | Cleanser composition | |
| JP5455292B2 (en) | Skin external composition | |
| JP2007001924A (en) | Skin care preparation | |
| JP3507635B2 (en) | Composition suitable for external use | |
| CN115444766A (en) | Double-component shampoo with scalp nourishing effect and preparation method thereof | |
| JPH06279294A (en) | Collagen synthesis promoter | |
| JP2008094799A (en) | Sulfated glycosaminoglycan production promoter and external preparation for skin containing the same | |
| KR102337667B1 (en) | Cosmetic composition for skin moisture and manufacturing method thereof |